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Hepatitis C virus (HCV) is characterized by considerable genetic variability and, as a consequence, it has
6 genotypes and multitude of subtypes. HCV envelope glycoproteins are involved in the virion formation;
the correct folding of these proteins plays the key role in virus infectivity. Glycosylation at certain sites of
different genotypes HCV glycoproteins shows substantial differences in functions of the individual glycans
(Goffard et al., 2005; Helle et al., 2010) [1,2]. In this study, differential glycosylation sites of HCV genotype
1b envelope proteins in insect and mammalian cells was demonstrated. We showed that part of glyco-
sylation sites was important for folding of the proteins involved in the formation of viral particles. Point
mutations were introduced in the protein N-glycosylation sites of HCV (genotype 1b) and the mutant
proteins were analyzed using baculovirus expression system in mammalian and insect cells. Our data
showed that, in contrast to HCV 1a and 2a, the folding of HCV 1b envelope proteins E2 (sites N1, N2, N10)
and E1 (sites N1, N5) was disrupted, however that did not prevent the formation of virus-like particles
(VLP) with misfolded glycoproteins having densities typical for HCV particles containing RNA fragments.
Experimental data are supported by mathematical modeling of the structure of E1 mutant variants.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C infection is being called a silent epidemic (HCV
currently infected about 3% of the global population). Modern
methods of hepatitis C treatment are not perfect, and more de-
tailed knowledge of HCV remains insufﬁcient [3].
The HCV is characterized by considerable genetic variability
and, as a consequence, by the presence of 6 genotypes and several
dozens of subtypes. One of the main HCV subtypes predominating
in many countries including Russia is genotype 1b which is re-
sistant to interferon therapy. Despite the creation of the direct-
acting antivirals for the treatment of HCV infection which ap-
peared in the last few years [4–7] the studies of the molecular
mechanisms of viableHCV 1b virion formation that determine the
infectivity of the virus, including its morphogenesis and patho-
genesis are of great need.
The speciﬁc feature of HCV is its high replicative activity
leading to high genetic variation and the expressed ability toB.V. This is an open access article umutate. The maximal variability is observed in genes encoding the
envelope glycoproteins, E1 and E2. As a result, infected patients at
various stages of infection may have several dozens of HCV sub-
types as a set of closely related genomes within the same geno-
type. Some viral strains are characterized by a higher degree of
pathogenicity, but speciﬁc molecular determinants of such phe-
notype are not clear.
In an infected cell, the formation of infectious viral particles
occurs with participation of various HCV components, including
envelope glycoproteins. These proteins, E1 and E2, undergo post-
translational N-glycosylation, wherein the low-branched oligo-
saccharide chain consists of nine residues of mannose (Man) and
three residual glucose (Glc), attached to speciﬁc residues asparagine
Asn-X-Ser or Asn-X-Thr sequences (where X – any amino acid ex-
cept proline) [8]. HCV virion envelope glycoproteins are highly
glycosylated; the high degree of conservation of glycosylation sites
4–5 in E1 and 9–11 in E2 indicates their important role in the HCV
life cycle [2,9]. After glycosylation glycoproteins E1 and E2 HCV can
either dimerize to form a functional non-covalent complexes with
the participation of the cellular chaperone calnexin, or form dis-
ulﬁde bridges with the participation of cellular protein calreticulin
resulting in the formation of non-functional aggregates containingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primers used for site-speciﬁc mutagenesis.
Primer Orientation Nucleotide sequence 5′-3′
16-Haml þ ccactacgacaatac g
15-Hamr – gag caagtcgacgtg
26-E1N5tl þ ggactgccaatgctcaatctatcc cg
17-E1N6tl þ tggtcacttacaacagc
23-E1N5br – gag cat tggcagtcctgc act gt
17-E1N6br – ctgttgtaagtgaacag
17-E1N7tl þ gaactggtctaaggttc
17-E1N7br – aaccttagaagaccaggt cc
24r-Hpsr – cagctgcagttacccgtcaacgcc
29-E1N1m – ttatgaagtgcgccaagtgtccgg cat at
30-E1N2m – aacgactgctcccaatcaagcattgcg tat
27-E1N3m – gttcag gag ggtcaaagctcccgttgc
24-E1N4m – cgcggccaggcaagccagcgtccc
19 Haml – cactacgacaatacgacg t
18 Hamr – agcaagtcgacgtgacgt
28-E2N1m – tgaat acc caaggcagctggcac at
30-E2N2m – tggcacatccaaagt act gccctaaattgc
30-E2N3m – gccctaaattgccaagactccctccaa act
30-E2N4m – gcacacaagttccaatcgtccgggtgcccg
25-E2N6m – tggggg gag caa gag acagacgtg a
30-E2N7m – gtgatgctcctccaaaacacgcgtccgcca
30-E2N8m – tgtacatggatgcaaagt act gggttc act
27-E2N9m – ggggtcggtcaacgc acc ttgaattgc
30-E2N10m – tacccctgc act ctccaatttttc cat cat
27-E2N11m – gccgcatgccaatgg act cgagga gag cgc
E2 for þ aggtctagaatgttatgattgttttgctac
E2 back þ ct atagtgtcacctaaatccgaaagcttcggcctcagcttgag
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aggregates may lead to the production of defective viral particles
that can possibly inhibit the ability of the virus' input and output of
the cell. It is not clear whether the aggregates are formed in the
course of HCV infection. Studies related to the glycosylation of the
recombinant mutant HCV envelope glycoproteins in HCVpp and
HCVcc systems show some glycans that are important in viral as-
sembly, its cell-binding ability and protection from neutralizing
antibodies [12,13]. Furthermore, these oligosaccharides form the
N-linked “glycan shield” on the virion surface, which contributes to
HCV avoidance of humoral immune response. Thus, glycosylation of
HCV envelope protein may play an important role at various stages
of the viral life cycle. Investigation of the role of N-glycans in
functioning of the HCV envelope proteins of different genotypes is
important for understanding of the mechanisms of viral infection
and the development of new antiviral drugs. In this work we used
the E1 and E2 glycoproteins of hepatitis C virus genotype 1b (strain
274933RU [14]) with point mutations in the N-linked glycosylation
sites to determine the role of these glycans in the HCV envelope
proteins functioning. Protein mutants were analyzed in the model
system of virus-like particles in insect Sf9 and mammalian Hek293T
cells using the baculovirus expression system. The data obtained
demonstrate the inﬂuence of N-glycans localized in speciﬁc sites of
glycosylation of E1 and E2 on their interactions, E1E2 heterodimer
formation and HCV VLP assembly. Mutations at these positions do
not prevent the formation of VLPs in insect and mammalian cells.
VLPs have a density typical of HCV particles and bind to CD81-he-
patoma cell in an independent manner. Computer calculations of 3D
models of the mutant E1 protein molecules complement the ex-
perimental data.2. Materials and methods
2.1. Bacterial strains, cells, and plasmids
Escherichia coli, insect Sf9, and mammalian Hek293T and
Huh7.0 cells were used. Bacterial cells of the DH5a and DH10Bac
strains (Gibco-BRL, USA) were transformed with the plasmid DNA
according to the recommendations of the manufacturer (Amer-
sham, USA). Isolation and puriﬁcation of plasmids, restriction en-
donucleasedigestion, ligation, agarose gel electrophoresis of DNA,
and other genetic engineering experiments were carried out using
standard protocols [15].
2.2. Insect cells
The Spodoptera frugiperda Sf9 cells were cultured at 27 °C in a
Sf-900 II medium supplemented with 10% fetal bovine serum,
following the basic procedures that were previously discussed and
described in the protocol [16]. To determine the virus titer, am-
pliﬁcation of recombinant virus, infection of Sf9 cells with re-
combinant baculovirus, and analysis of viral gene expression, the
same protocol was used.
2.3. Human embryonic kidney
293T cells (Hek293T) were cultured at 37 °C and 5% CO2 in
DMEM media supplemented with 10% fetal bovine serum, 4 mM L-
glutamine, 1 mM sodium pyruvate, and streptomycin/penicillin at
the concentrations of 100 μg/mL and 100 U/mL, respectively.
2.4. Recombinant constructs
Carrying cDNAs corresponding to the genes of HCV structural
proteins, recombinant bacmids, as well as recombinantbaculovirus bv-CE1E2, were obtained and analyzed according to
standard protocols and previously tried techniques [17].
2.5. Site-directed mutagenesis
Using oligonucleotide-directed mutagenesis with double-
stranded plasmid vectors, point mutations were introduced in the
N-linked glycosylation sites of the HCV E1 and E2, and the genetic
constructs coding the mutant proteins were obtained. To introduce
mutations into prescribed positions of the E1 and E2 cDNA se-
quences, oligonucleotide primers, presented in Table 1, were
designed.
Each primer consisted of 16–30 nucleotides and contained the
sequence encoding the N-glycosylation site: Asn-X-Thr/Ser-X (X-
any amino acid, except proline), in which the triplet encoding
asparagine (Asn) was substituted with the triplet encoding gluta-
mine (Gln). The method described by Drutsaet al. [18] was used for
mutagenesis. PCR was performed on the CycloTemp 107 pro-
grammable thermocycler (ResursPribor, Russia). Predetermined
base substitutions were veriﬁed by sequencing. The DNA fragment
containing cDNA sequence of the gene encoding the HCV glyco-
protein E1 was cloned into the pBluescriptKS(-) plasmid at the
ClaI-PstI sites. The DNA fragment containing cDNA sequence of the
gene encoding the HCV glycoprotein E2 was cloned into the
pFastBacHTb plasmid at the NcoI–EcoRI sites. This made possible
to construct a series of recombinant pBluescriptKS-E1mut and
pFastBacHTbE2mut plasmids carrying cDNA of the E1 and E2
proteins with point substitutions at glycosylation sites. As a result,
the baculovirus expression vectors carrying the cDNA of E1mut
(pFastBacHTbE1mut, pFastBacHTbE1mutE2, and based on the
pFastBacMam1GFP, the BacMamCE1mutE2GFP vector DNA) and
the cDNA of E2mut (pFastBacHTbE2mut, pFastBacHTbE1E2mut,
pBacmamCE1E2mutGFP) were obtained.
2.6. Analysis of total cellular DNA
Total cellular DNAwas isolated from insect cells 72 h after infection
with the bv-CE1E2, bv-E2mut, bv-E1mut, bv-E1E2mut, bv-E1mutE2,
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of infection being 5 CFU per cell) [19]. The presence of cDNA of HCV
structural proteins in total cellular DNA was assessed by PCR with
primers for the pFastBacHT baculovirus vector (forward 5′-
GTGGTTGGCTACGTATACTCC-3′ and reverse 5′-CCTCTACAAATGTGGT-
ATGGC-3′).
2.7. Analysis of HCV RNA by RT-PCR
The Sf9 cells were infected with the bv-CE1E2mut recombinant
baculoviruses (5 CFU per cell) and incubated at 27 °C for 72 h. After
72 h, the medium was eliminated and cell debris was removed by
low-speed centrifugation. The supernatant was centrifuged
through the 30% sucrose cushion at 23000g for 16 h at 4 °C
(Beckman Coulter Optima L-100XP centrifuge, 80Ti rotor). RNA
was extracted from the pellet with TRIzol (Invitrogen) according to
manufacturer's protocol and treated with DNase I (Promega). Re-
verse transcription was carried out using the Phusion RT-PCR Kit
(Thermo Scientiﬁc). The obtained cDNA was ampliﬁed using PCR
with primers for the genes of structural and nonstructural HCV
proteins. Total cellular RNA was extracted from Sf9 cells infected
with bv-CE1E2mut or bv-CE1mut E2 (5 CFU per cell) that were
incubated at 27 °C for 72 h and washed three times with PBS. RNA
isolation, reverse transcription, and ampliﬁcation were performed
using the above-mentioned protocols. The Hek293T cells were
transfected with the BacMamCE1E2mut-GFP recombinant plas-
mids or the BacMamCE1mut E2-GFP (5 CFU per cell) and in-
cubated at 37 °C for 48 h. The medium was removed and RNA
isolation, reverse transcription, and ampliﬁcation were performed
using the above-mentioned protocols.
2.8. Anti-HCV antibodies
Mouse monoclonal antibodies to the HCV E1 (Hep C E1 1879:
sc-65459) and HCV E2 (Hep C E2 BDI167: sc-57769) (Santa Cruz
Biotechnology, USA) proteins, as well as monoclonal antibodies to
calnexin (AF18) and calreticulin (FMC75) (Abcam, UK), were used.
Rabbit polyclonal anti-protein C antibodies were kindly provided
by M.G. Isaguliants (Ivanovsky Institute of Virology, Russian
Academy of Sciences, Moscow). Anti-mouse IgG antibodies
(AB6706-1EA) conjugated to horseradish peroxidase (Sigma, USA)
were used as secondary antibodies.
2.9. Western blotting and immunoprecipitation
After 72 h of infection with the bv-E2mut, bv-E1mut, bv-
E1E2mut, bv-E1mutE2, bv-CE1E2mut, bv-CE1mutE2 recombinant
baculoviruses (multiplicity of infection of 5 CFU per cell), the Sf9
cells were harvested, washed three times with PBS (1.47 mM
KH2PO4, 4.29 mMNa2HPO4 7H2O, 137 mM NaCl, 2.68 mM KCl),
resuspended in the TNC lysis buffer containing 0.25% digitonin,
and disrupted by sonication. Cell debris was removed by cen-
trifugation (15,000g, 15 min, 4 °C). Cell lysate was loaded into a
12% denaturing gel (each sample contained 10 μg of the protein).
After electrophoresis, the proteins were transferred onto the Hy-
bond-ECL nitrocellulose membrane (Amersham Biosciences, USA)
using semi-dry electrophoretic transfer. The membranes were
washed with PBS containing 5% nonfat dry milk, incubated with
primary antibodies to the HCV structural proteins E1 or E2 (dilu-
tion 1:1500 for E1 and 1:2000 for E2), to calnexin or calreticulin
(dilutions 1:1000 and 1:2000, respectively), and then to secondary
antibodies (dilution 1: 20,000). Protein complexes on im-
munoblots were detected using the ECL and ECL Plus chemilumi-
nescent reagents (Western blotting detection reagents and analy-
sis systems, Amersham Biosciences, USA) as recommended by the
manufacturer. For immunoprecipitation, the cells infected with therecombinant baculoviruses were harvested after 72 h of infection;
the cells were lysed, and the cell debris and nuclei were removed.
Structural proteins and their complexes were precipitated by
monoclonal antibodies to HCV E1 and HCV E2, calnexin and cal-
reticulin in a dilution of 1:1000 (as recommended by the manu-
facturer). The precipitated proteins were separated by electro-
phoresis in 12% PAGE, transferred onto a nitrocellulose membrane,
incubated with primary antibodies in the above-mentioned dilu-
tions, and then, treated with secondary antibodies.
2.10. Endoglycosidase H (Endo H) treatment
The proteins of cell lysate were incubated with the corre-
sponding monoclonal antibodies at 4 °C. The obtained complex
was precipitated with protein G sepharose (BioVision, USA). The
precipitated protein (20 μg) was mixed with 1 μl of the 10 de-
naturing buffer (5%SDS, 0.4 M DTT), the volume of the mixture was
adjusted to 10 μl with water, and the mixture was boiled for
10 min. Next, the total volume was adjusted to 20 μl by adding 2 μl
of the 10G5 reaction buffer (50 mM sodium citrate), 3 μl of
water, and 5 μl of the Endo H solution (5 units) (P0702S BioLabs
Inc., United Kingdom). The mixture was incubated for 15 min at
37 °C and analyzed by electrophoresis in 12% PAGE.
2.11. Preparation and puriﬁcation of virus-like particles (VLP)
The cells growing in monolayer at 27 °C infected with the bv-
CE1E2 recombinant baculovirus (10 CFU per cell). After 72 h, the
cells (2108) were harvested, washed three times with PBS, re-
suspended in TNC lysis buffer (10 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1 mM CaCl2, 1 mM PMSF), protease inhibitors cocktail II
(Calbiochem, USA) (1:200) containing 0.25% digitonin, and dis-
rupted by sonication. VLPs extracted from homogenized lysates
were puriﬁed from cell debris with the help of low-speed cen-
trifugation (1200g, 15 min, 4 °C). Then, VLP were concentrated by
centrifugation through the 30% sucrose cushion at 23,000g for 16 h
at 4 °C. The VLP precipitate was re-suspended in TNC buffer con-
taining 1 mM PMSF, protease inhibitors (1:200), and analyzed
using sucrose gradient centrifugation.
2.12. Sucrose gradient centrifugation
The VLP precipitate re-suspended in a 100 μl of TNC buffer
containing 1 mM PMSF and protease inhibitors (1:200) was placed
layer after layer on the sucrose solutions of different concentration
(from 10 to 60% in 50 mM Tris–HCl, 100 mM NaCl, pH 7.4) and
centrifuged at 20,000g for 2.5 h at 4 °C (Beckman Coulter Optima
L-100XP centrifuge, 80Ti rotor). Ten 1-mL fractions were collected,
and each fraction was concentrated by high-speed ultracentrifuga-
tion at 230,000g for 16 h at 4 °C. The precipitate was dissolved in
100 μl of TNC buffer containing 1 mM PMSF and protease inhibitors
(1:200) and analyzed using Western blotting [15,19].
2.13. Analysis of the VLP binding to CD-81 receptor
Huh7 cells were incubated in the presence of VLP, produced in
Sf9 cells, for 1 h at 4 °C. Huh7 cells pre-incubated with anti-CD81
antibodies (20 μg/mL) for 1 h at 4 °C to block the CD81 receptor
were used as a control. The cells were harvested, washed twice
with PBS to remove unbound VLPs, and analyzed using Western
blotting with anti-E2 antibodies.
2.14. Fluorescent microscopy and ﬂow cytometry
After transfection for 48 h with recombinant BacMam-
CE1E2GFP plasmids, Hek293T cells were trypsinized, collected by
Fig. 1. N-glycosylation sites of the HCV E1 and E2 structural proteins and their mutant variants. A, schematic representation of the mutant variants of glycoprotein E1 with
modiﬁed glycosylation sites: 1, N1; 2, N5; 3, N1 and N5; 4, N2, N3, and N4; 5, N2, N3, N4, and N5; 6, N1, N2, N3, and N5; 7, N1—N5; 8, N1, N2, N3 and N4; 9, with additionally
introduced N6 glycosylation site; 6, initial wildtype E1 variant. B, schematic representation of the mutant variants of glycoprotein E2 with modiﬁed glycosylation sites: 1, N1;
2, N2; 3, N3; 4, N4; 5, initial wildtype E2 variant, containing in 4% of genotype 1b strains glycosylation site N5; 6, N6; 7, N7; 8, N8; 9, N9; 10, N10; 11, N11; 12, N1, N2, N3, N4,
N6, N7(mL); 13, N8, N9, N10, N11(mR); 14, N1-N11(ΣN). C, expression analysis of the HCV envelope-encoding genes synthesized in insect cells infected with the bv-E1E2
baculovirus. Western blot analysis of glycoprotein expression in the presence and absence of tunicamycin and glycoproteins treated with EndoH endonuclease, in dena-
turating 12% PAGE with anti-E2 antibodies. Lysates of the cells infected with recombinant baculoviruses synthesizing E1 and E2: WT, wildtype E1E2; N10, E2 with mutations
at the N10 glycosylation site; C, negative control (Hsp90); kDa, protein molecular size markers.
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analyzed by ﬂow cytoﬂuorometry (Beckman Coulter EPICS, USA)
and Western blotting.2.15. Mathematical modeling of the 3D structure of HCV E1 mutant
protein
Computer calculations for different fragments of the E1 protein
molecules in vacuum and in aqueous environment with the
methods of molecular mechanics (energy optimization) and either
molecular, or Langevin dynamics were used. The calculations were
performed in the HyperChem v.6.01 computational chemistry
program (Hypercube, Inc USA) [20,21], which contains the data-
bases for introduction of amino acids using the 1800 MHz AMD
processor. To estimate the shape of the E1 molecule and the effect
of N-glycans and water, ten variants of HCV E1 mutant protein
(Fig. 1A) with the deleted C-terminal sequence were used. Test
calculations were carried out on the E1 fragments of different
length and extrapolated to the whole E1 molecule. Five fragments
of the protein molecule of different lengths, including 19 amino
acids, 268 atoms; 38 amino acids, 538 atoms; 76 amino acids, 1098
atoms; 133 amino acids, 1952 atoms; the whole E1 molecule, de-
void of glycans; and 250 amino acids, 3739 atoms were used.
Calculations of the protein shape were performed as follows:
protein sequence was formed using amino acid residues from the
HyperChem database with the angles between the individual
atoms within each amino acid residue in the E1 molecules of
different length. Then, the angles between atoms of the amino acid
residues were set. As a result, the preliminary three-dimensional
structure of the E1 protein molecule was obtained. Next, the
procedure of the molecule energy minimization was carried out.
To optimize the geometry of the E1 protein structure, the positions
of all atoms of the amino acid residues were selected to minimize
the energy at the time of determining the total energy of the
molecule. Free energy, dipole moment, and the geometric di-
mensions of each structure were calculated, which showed how
the molecule under investigation was folded. Then, the calculation
of either molecular or Langevin dynamics was run, and then
geometric optimization and the process were repeated minimizing
the energy of the molecule to the optimum geometry, whereby
coiled molecules acquired speciﬁc conformation.3. Results and discussion
The study of conformational changes and the interactions be-
tween HCV envelope proteins and their glycosylation in the model
system of virus-like particles formed in the cells of insects and
mammals makes it possible to understand the role of glycosylation
of the genotype 1b HCV in viral morphogenesis. The glycosylation
pattern of viral genotype 1b differs from the extensively studied
genotypes 1a and 2a. This difference consists in the presence of
the N4 glycosylation site in glycoprotein E1, and the absence of N5
glycosylation site in the HCV E2 protein. There are considerable
differences in the functions of individual glycans within different
genotypes of hepatitis C virus. In this study, the role of glycans
associated with the envelope proteins of HCV genotype 1 b (strain
274933RU) in the protein folding and assembly of viral particles in
two different cell types were analyzed in the baculovirus expres-
sion system, using site-directed mutagenesis of glycoproteins
[14,17]. Point mutations were introduced into the predetermined
positions of the E1 and E2 cDNA nucleotide sequences harboring
N- glycosylation sites, using the appropriate primers (Table 1).
Based on the baculovirus expression vectors, pFastBacHTb and
pFastBacMam1GFP, carrying the E1 and E2 sequences with point
substitutions at glycosylation sites (see Section 2), in insect and
mammalian cells, mutant HCV envelope proteins were synthe-
sized (Fig. 1A and B).
3.1. The effect of N-glycans on expression of viral envelope protein
genes in insect and mammalian cells
It is known that N-glycosylation pathways in the cells of Spo-
doptera frugiperda, which may lack the appropriate glycosyl-
transferases, are not always completely the same as in mammalian
cells. Fig. 1С shows that the synthesis of HCV envelope proteins, as
well as their effective post-translational glycosylation takes place
in insect cells. This concerns both wildtype proteins and their
mutant variants, sensitive to the presence of tunicamycin and
EndoH endoglycosidase.
In Sf9 insect cells the disruption of glycosylation sites in various
combinations of E1 and E2 glycoproteins (except for the N6 site),
had no effect on the synthesis efﬁciency of these proteins, which
follows from the results of electrophoresis in PAGE and im-
munoblotting with antibodies to these proteins (data not shown).
At the same time, ﬂow cytometry data showed that in Hek293T
mammalian cells, the absence of carbohydrate chains in the E1
Fig. 2. Gene expression analysis of mutant E1 and E2 proteins within the HCV CE1E2 polypeptide in mammalian cells.A, Assessment of the GFP ﬂuorescence in HEK293T cells
transfected with the pFastBacMamCE1E2GFP plasmids with different mutations in the E1 gene by ﬂow cytoﬂuorometry. Linear sizes of the examined particles (cells) in
relative units are marked on the X-axis of the histogram, and relative values of the ﬂuorescence intensity are marked along the Y-axis. Hek293T, initial cells; cells transfected
with the pFastBacMamCE1E2GFP with the E1 gene: WT, wildtype E1; E1 with mutation at the N1 glycosylation site; N5; N2, N3, and N4; N1 and N5; N1—N5. B, Assessment
of the GFP ﬂuorescence in HEK293T cells transfected with pFastBacMamCE1E2GFP carrying mutations in the E2 gene by ﬂow cytoﬂuorometry. Relative values of the
ﬂuorescence intensity are plotted on the Y-axis; On the X-axis, cells expressing: WT, wildtype E2; E2 with mutations at N1, N2, N4, N8, N10, mL(N1—N7), mR(N8—N11), and
ΣN(N1—N11) glycosylation sites are marked; C, negative control (Hsp90).
Fig. 3. Gene expression analysis of mutant E1 and E2 proteins within the HCV E1E2
in Sf9 cells. A, Western blotting in 10% PAGE with anti-calnexin antibodies and B,
with anti-calreticulin antibodies, after preliminary immunoprecipitation with anti-
E2 antibodies. Lysates of the cells infected with recombinant baculoviruses ex-
pressing E1: WT, wildtype E1; E1 with mutations at the glycosylation sites N3; N5;
N1 and N5; N1 and N5; N1—N5. kDa, protein molecular size markers. C, Gene
expression analysis of mutant E2 proteins of HCV in Sf9 cells.Western blotting in
10% PAGE with anti-calreticulin antibodies. Lysates of the cells infected with re-
combinant baculoviruses expressing E2: WT, wildtype E2; E2 with mutations at N1,
N2, N3, N4; N6; N7, N8; N9; N10; N11; N1—N7(mL); N8—N11(mR); N1—N11(ΣN),
at all E2 glycosylation sites; C, negative control (Hsp90); kDa, protein molecular
size markers. Mutant proteins are designated as E2*.
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resulted in considerable reduction of the expression level of these
glycoproteins as the parts of CE1E2GFP polypeptides, compared to
the initial polypeptides. These data are supported by the decrease
in the GFP ﬂuorescence (Fig. 2A and B).
3.2. The effect of N-glycans of HCV envelope glycoproteins on the
formation of productive E1E2 complex in insect cells
It is suggested, that glycans associated with the viral envelope,
affect the correct folding of glycoproteins with the participation of
ER chaperones [10]. Glycoproteins are then combined into func-
tional complexes deﬁning productive assembly of viral particles in
the cells. The effect of mutations in glycosylation sites of HCV E1
and E2 proteins on their folding and the formation of E1E2 com-
plexes in insect cells was assessed by their interaction with cellular
chaperones calnexin and calreticulin. Apparently, in insect cells,
the mutant glycoproteins E1 and E2 speciﬁcally interact with
calnexin, indicating the formation of correctly folded functional
proteins and the E1E2 heterodimers. At the same time, aggregates
of misfolded E1E2 dimers interact with calreticulin [1]. It wasfound that assembly of noncovalently bound HCV E1E2 complex in
insect cells depended on the disruption of N1 and N5 glycosylation
sites of E1 and was broken as a result of disruption of one of the
N1, N2, or N10 sites of the HCV glycoprotein E2 (Fig. 3A and B).
It seems likely that mutations at these E1 and E2 glycosylation
sites prevent the proteins constituting functional E1E2 complex from
assuming their proper conformation, while mutations at other sites
do not disturb this process. As the number of damaged sites increases
(N1–N7 (mL) and N8–N11 (mR)), assembly of the productive E1E2
complex reduces with the formation of the aggregates of the mis-
folded E1E2 dimers, interacting with calreticulin (Fig. 3C).
Thus, it is obvious that the glycans associated with the HCV E1
glycosylation sites N1 and N5, and E2 glycosylation sites N1, N2,
and N10 are important to stabilize the structure of these proteins,
and play an important role in their correct conformation when
forming a functional complex and, accordingly, in the productive
assembly of virus particles in Sf9 cells.
3.3. The effect of N-glycans of HCV envelope glycoproteins on the
formation of virus-like particles in insect and mammalian cells
It is known that efﬁcient expression of the HCV structural
proteins in insect cells is accompanied by the formation of virus-
like particles. We showed that in these cells infected with the bv-
CE1E2 recombinant baculovirus the synthesized VLP were loca-
lized on the ER membranes and were not secreted into the culture
medium. Electron microscopy of microsomal and puriﬁed VLP
preparations is demonstrated in Fig. 4A, and electron microscopy
of VLP in the microsomal fractions of Sf9 cells infected with the bv-
CE1E2 baculoviruses synthesizing mutant E1 is shown in Fig. 4B.
(see Section 2).
It was found that the absence of glycans in the E1 glycosylation
sites had no effect on the VLP formation in insect cells (Fig. 4B).
These results were also conﬁrmed by PAGE electrophoresis and
Western blotting with the antibody to E2 (data not shown).
The effect of the glycosylation sites disruption in E2 glycoprotein
as the component of CE1E2 on the assembly of functional glyco-
protein complexes, and respectively, the CE1E2 packaging in VLP in
Sf9 and Hek293T cells, was assessed by speciﬁc interaction of mutant
glycoproteins with calnexin and calreticulin. Gene expression ana-
lysis of mutant E2 proteins as the components of HCV CE1E2 in
mammalian Hek293T cells is demonstrated in Fig. 5A and B.
Fig. 4. A, electron microscopy of microsomal preparations (a) and puriﬁed VLP preparations (b). The preparations were obtained from the Sf9 cells infected with re-
combinant baculoviruses: 1, bv-CAT/GUS (control); 2, bv-CE1E2; 3, bv-CþE1þE2 (co-transfection); B, electron microscopy of VLPs in microsomal fractions of the Sf9 cells
infected with bv-CE1E2 baculoviruses, synthesizing: WT, wildtype E1; E1 with mutation at the N1; N5; N2, N3, and N4; N1—N5 glycosylation site; CAT/GUS, negative
control. The position of VLP is indicated by the arrows.
Fig. 5. Gene expression analysis of mutant E2 proteins as parts of the HCV CE1E2 in
mammalian Hek293T cells. A, Western blotting in denaturating 10% PAGE with
anti-calnexin antibodies and B, with anti-calreticulin antibodies. Lysates of the cells
transfected with the recombinant pFastBacMamCE1E2mutGFP plasmids synthe-
sizing E2 with mutations at glycosylation sites: N1; N2; N4; N8; N10; N1—N7(mL);
N8—N11(ΣN), at all glycosylation sites; WT, wildtype E2; C- negative control
(Hsp90). C, with anti - β– actin antibodies; kDa, protein molecular size markers;
Mutant proteins are designated as E2*.
Fig. 6. Analysis of the HCV-like particles isolated from Hek293T cells by cen-
trifugation in sucrose gradient. Western blotting of ten VLP fractions, top-to-bot-
tom, in denaturating 10% PAGE, with antibodies to HCV C (Core) and E2. Hek293T
cells were transfected with recombinant pFastBacMamCE1E2mutGFP: A, intact
DNA; B, DNA with mutation at the E2 N1 glycosylation site; C, with mutations at all
E2 glycosylation sites; Fractions 1—10; kDa, protein molecular size markers.
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CE1E2 in insect (data not shown) and mammalian cells showed that
disruption of glycosylation sites in different combinations (except for
the N6 site) had no effect on formation of the functional E1E2 het-
erodimers, and correspondingly, on the CE1E2 packaging within
HCV. At the same time, disruption of the E2 N1, N2, and N10 sites led
to formation of the aggregates of misfolded glycoproteins in the E1E2
complex that also did not prevent the formation of VLPs. Obviously,
the produced VLP contain nonfunctional E1E2 complexes with mis-
folded mutant glycoproteins. The HCV-like particles formed in
Hek293T cells, transfected with recombinant pFastBacMamCE1E2-
mutGFP, were also evaluated for their physical characteristics. For
these purposes, VLPs were puriﬁed and concentrated by centrifuga-
tion through the cushion of 30% sucrose at 23,000g, and the VLP
precipitate was then analyzed using centrifugation in sucrose gra-
dient. The collected fractions were compared by sedimentation at a
density typical for the hepatitis C virus particles (from 1.14 to 1.16 g/
cm3) and analyzed by Western blotting using antibodies to structural
proteins (Fig. 6A, B, and C).
Immunoblotting using antibodies to the C (Core) and E2 pro-
teins revealed that VLPs were present in all fractions with the
density of 1.14–1.16 g/cm3. This ﬁnding can be an indication that
RNA fragments are present in VLPs [22].
As follows from the data obtained, the introduction of muta-
tions at glycosylation sites of virus envelope glycoproteins does
not prevent the formation of virus-like particles of the hepatitis C
virus in insect and mammalian cells. However, it seems likely that
HCV VLPs formed with the participation of E1N1, E1N5, E2N1,
E2N2, and E2N10 mutant glycoproteins may contain the protein
E1E2 complex with the disrupted conformation that prevent theformation of the proper virus particles in the cells. To conﬁrm our
results and the conclusion on defective conformation of certain
mutant HCV envelope glycoproteins synthesized in insect cells,
computer models of the spatial structure of mutant E1 proteins,
with and without N-glycans were constructed.
3.4. The effect of N-glycans of hepatitis C virus E1 envelope glyco-
protein on its 3D structure
One of the possible ways to conﬁrm the results obtained in a
chemical experiment is the mathematical modeling of the 3D protein
Fig. 7. A, Dependency between the computer processing time and the number of atoms in the E1 molecule required for the full calculation of the optimum geometry of the
molecule. On abscissa, the number of atoms; on ordinate, CPU time in hours. Three-dimensional structure of mutant HCV E1 protein molecules: B, Amino acid sequence of
wildtype HCV E1 protein with 218 aa. The glycan attachment sites are underlined. , the ﬁrst amino-acid residue protruding from the membrane. , the closest to the
membrane asparagine to which glycan is attached; C, Computer models of mutant E1 glycoprotein variants with the disrupted glycosylation sites (N1—N6): 1, N1; 2, N5; 3,
N1, N5; 4, N2, N3, and N4; 5, N2, N3, N4, and N5; 6, N1, N2, N3, and N5; 7, N1—N5; 8, N1, N2, N3, and N4; 9, with the additional glycosylation site N6; 10, initial variant of
wildtype E1; – , the E1 membrane-anchoring site. The E1 protein is oriented so that the locates at the origin of the axis Oy, and lies in the picture plane or in the
plane Oxy. The scale of each protein variant was adjusted so that the sizes of all carbon atoms (light blue), or nitrogen (blue), or oxygen (red) or sulfur (yellow) were the same
for all ten variants. Hydrogen is not shown. Glycans are in green color.
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using the method of molecular dynamics as implemented in the
HyperChem software program, optimal geometry of the E1 mole-
cules were calculated and a computer model of the spatial structure
of the mutant E1 protein was constructed. Since in the HyperChem
program the geometry optimization procedure results in the loss of
time in comparison with the computation of the same molecule, for
example, in the NAMD and GROMACS programs, we compensated
this drawback by increasing the processing time spent for the cal-
culation. We examined the molecular conformations of ten HCV E1
protein variants with the deleted C-terminal sequence (Fig. 7) and
with different number of glycans and their arrangement. Test cal-
culations were carried out using fragments of the molecules of dif-
ferent lengths and extrapolated to the whole E1 molecule. To select
the criteria necessary for the full calculation of the optimum geo-
metry of E1 molecules, both wildtype and mutant, test calculation of
the E1 protein fragment of 38 aa (538 atoms), devoid of all glycans
was performed. The computation showed that the total energy and
geometrical characteristics simultaneously came to the value char-
acterizing optimal conﬁguration of the E1 fragment (graphs not
shown). Determination of the effect of the molecular dynamicscomputation time on the geometry of molecule indicated that the
time step had no effect on the ﬁnal geometry of the molecule. The
achievement of the optimum geometry of the molecule depends on
the total time duration. The most informative criterion for the opti-
mum geometry of the protein molecule is that the molecular energy
has reached its plateau value. To ﬁnd the time-dependence between
the Langevin dynamics counts and the number of atoms in a mole-
cule, required to reach a plateau of minimum energy, we conducted a
test calculations for ﬁve E1 protein fragments of varying length (see
Section 2). The total energy and geometric characteristics were de-
termined in each of ﬁve E1 fragments. For all ﬁve E1 molecules, the
time-to-reach a plateau was about 75, 150, 300, 500, and 1200 ps.
Using these data, we determined the time required for the full cal-
culation of the optimum geometry of the E1 molecules on the PC
used. The dependency between the computer processing time and
the number of atoms in the E1 molecule required for the full calcu-
lation of the optimum geometry of the molecules is shown in Fig. 7A.
Interestingly, extrapolation of power dependence for 3D protein
structure on the graph shows the exponent¼2.7853, close to three. A
similar relationship is shown in [23]. The amino acid sequence of the
wildtype HCV E1 genotype 1b protein (strain 274933RU) with 218 aa
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with mutations are shown in Fig. 7B and C.
The data obtained demonstrate various mutant protein struc-
tures that differ from the structure of the original wildtype HCV E1
protein (Fig. 7C, No. 10). The absence of carbohydrate chains at the
N1 or N5E1 glycosylation sites leads to misfolding of these pro-
teins and formation of the similar spatial structures (Fig. 7C, No.1,
N1; No.2, N5; No.3, N1, N5), that considerably differ from the
structure of the wildtype protein. These simulations favor the
suggestion that glycans, associated with the N1 and N5 sites, play
the most important role in proper E1 folding, required for the
formation of functional E1E2 complex. Three-dimensional struc-
tures of the other mutant protein variants showed the differences
in the conformation of the molecules lacking one or more glyco-
sylation sites. However, these differences, as it was demonstrated
in our in vitro biochemical experiments, did not lead to the for-
mation of unproductive E1E2 complexes. Thus, 3D structure
models of the E1 protein with mutations show that the N-linked
glycans directly affect the E1 folding, the shape of the molecule,
and, apparently, can play an important role in functioning of these
proteins. Molecular modeling data obtained in this study are
generally consistent with our experimental data.4. Conclusion
In this study, we showed that the HCV (genotype 1b, strain
274933RU) structural proteins are synthesized in the infected Sf9
insect and Hek293T mammalian cells using the baculovirus expres-
sion system. These proteins are subjected to post-translational
modiﬁcations and form virus-like particles that are localized in ER
membranes of the infected cells. The characterization of these par-
ticles by sucrose gradient centrifugation has revealed physical
properties similar to virus-like particles with the density of 1.14–
1.16 g/cm3 and containing RNA fragments. These results indicate that
glycosylation of viral envelope proteins expressed in Sf9 and
Hek293T cells affect their expression, processing and formation of
virus particles. Introduction of mutations at the glycoprotein glyco-
sylation sites does not prevent the formation of virus-like particles in
insect and mammals cells. However, the disruption of the HCV 1b E2
protein N1, N2, and N10 glycosylation sites, as well as E1 N1 and N5
sites, results in the formation of mostly unproductive E1E2 com-
plexes. Earlier Goffard et al. and Helle et al. showed that N1- and N5-
linked glycans of the HCV genotype 1a E1 protein also affected
folding of viral envelope proteins and the correct folding of viral
envelope glycoproteins of HCV genotypes 1a and 2a was affected by
the disruption of N-linked glycans of the E2 protein, different from
those examined in our study [1,2]. It is known that some E2 glycans,
depending on the strain of the virus, are critical for entry into the cell
and its infection. The E2 glycosylation sites are highly conservative,
and that indicates their important role in the HCV life cycle. Binding
of the virus particle to the hepatocyte cell-surface receptors and its
uptake into the cell is determined by viral envelope glycoproteins. It
was demonstrated that the effect of the CD81 receptor on binding of
the HCV-like particles of different genotypes to various cells (HepG2,
Huh7, NKNT-3, Molt-4) with the participation of envelope proteins
could be different [24,25]. We showed that HCV genotype 1b virus-
like particles, formed in the model baculovirus expression system,
bound to Huh-7 cells irrespective of the presence of the CD81 re-
ceptor on their surface and that mutations in the HCV E2 glycosy-
lation sites did not affect binding of viral particles to the CD81 re-
ceptor (publication in press). The obtained mathematical models of
3D structure of the mutant HCV E1 protein with different number of
glycans and their arrangement agree with the experimental data of
our study. They conﬁrm that the N-linked glycans have a direct effect
on the protein folding, demonstrating considerable differences in theconﬁguration of such molecules.
Thus, for the HCV genotype 1b (strain 274933RU) it was de-
monstrated that in Sf9 and Hek293T cells glycosylation of viral
envelope glycoproteins combined into functional glycoprotein
complexes affects the virion formation, which depends on correct
glycoprotein folding. According to our results, a combination of
experimental and computational approaches can be used in fur-
ther studies, associated with the effect of glycoprotein mutations
on viral replication, secretion of virus particles, as well as in those,
assessing the role of individual glycans of the HCV glycoproteins in
the interaction with cell receptors and viral entry into the cell.Acknowledgements
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